Trial Profile
Double-blind, Placebo-controlled, Clinical Trial on Efficacy and Safety of 12-months Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With P. Aeruginosa
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms PROMIS I
- Sponsors Zambon SpA
- 18 Jul 2023 According to a Zambon SpA Media Release, data from this study were presented at the 2023 6th World Bronchiectasis Conference in New York, NY.
- 18 Jul 2023 Results presented in a Zambon SpA Media Release.
- 21 Apr 2022 According to a Zambon SpA media release, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to colistimethate sodium powder for nebulization solution (CMS I-neb) for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa. The BDT is supported by data from this study.